Post ERCP Pancreatitis Prevention in Average Risk Patients
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Diclophenac potassium and ceftazidime are commercially available drugs that are used in
various clinical situations. They are safe and known for years. Diclophenac potassium and
Ceftazidime have been used in some studies for the prophylaxis and treatment of pancreatitis
and Post-ERCP Pancreatitis (PEP). Diclophenac potassium, together with indometacin is
currently standard treatment for prevention of (PEP) while ceftazidime is possible
alternative treatment for patients with contraindications for nonsteroidal medicines. The aim
of the study is to evaluate the efficacy of Ceftazidime for the prophylaxis of PEP.